In addition, the EMA has granted Priority Medicines (PRIME) eligibility for beti-cel. Approximately fifty adult and adolescent patients are enrolled in the study. Eli-cel has been granted Orphan Drug status by the FDA and EMA for adrenoleukodystrophy. Patients will be followed for 24 months post-treatment under this protocol. Target enrollment in ALD-104 is 35 patients. Cytopenias were common and not dose related. Sixty-nine patients received treatment as of the data cut-off. However, trade secrets can be difficult to protect. We have the right to grant sublicenses outright to third parties under the agreement. We must report on our progress towards achieving these milestones on an annual basis. Absent early termination, the license will expire in April 2037. This percentage varies from mid-single digits to low double digits. We may unilaterally terminate the license agreement upon six months' notice to MIT. For each such sublicense we grant we must pay the NIH a fee. Orphan product designation must be requested before submitting an NDA or BLA. As a result, increasingly high barriers are being erected to the entry of new products. We also have several programs in late-stage clinical development. We rely on a complex supply chain for ZYNTEGLO and our product candidates. Reimbursement agencies in Europe may be more conservative than CMS. There is a high failure rate for drugs and biologics proceeding through clinical studies. As of December 31, 2020, we had 1,201 full-time employees. Competition for skilled personnel is intense and the turnover rate can be high. These reductions were extended through 2029 through subsequent legislative amendments. Such a loss of patent protection would have a material adverse impact on our business. Changes in tax law could adversely affect our business and financial condition.
